All Tourmaline Bio articles

News

Novartis expands in cardiovascular disease with $1.4bn Tourmaline Bio acquisition

2025-09-09T13:21:30Z

Gains access to potential breakthrough atherosclerotic cardiovascular disease biologic therapy pacibekitug.